FibroGen Inc at Goldman Sachs Global Healthcare Conference Transcript
Okay, we'll continue with the next session. Good morning, everyone. I'm Paul Choi, the U.S. mid-cap biotechnology analyst here at Goldman Sachs. And in the audience here, from the team, we have Corinne Jenkins. Our next session will be with FibroGen. And to my left, from the management team, we have Dr. Tom Neff, CEO, who will introduce the rest of the team here for you to the audience.
Yes. Thank you, Paul. Dr. Peony Yu is on my immediate left, our Chief Medical Officer; and at the end, Dr. Elias Kouchakji, who is both Global Safety Head for the anemia program, roxadustat, and also the Head of Clinical Development for the pamrevlumab program. So that's the team for this morning.
Questions & Answers
Great. Thank you for that. So perhaps we'll kick off the Q&A and -- with perhaps an overview of the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
